Skip to main content
Erschienen in: Cancer Causes & Control 3/2013

01.03.2013 | Brief report

Diabetes and risk of bladder cancer among postmenopausal women in the Iowa women’s health study

verfasst von: Anna E. Prizment, Kristin E. Anderson, Jian-Min Yuan, Aaron R. Folsom

Erschienen in: Cancer Causes & Control | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Studies have indicated that diabetes is a risk factor for bladder cancer; however, many failed to adjust for confounding variables. An earlier publication from the Iowa Women’s Health Study reported a positive association of baseline diabetes with bladder cancer risk between 1986 and 1998, although the number of cases was small (n = 112). We re-examined the diabetes–bladder cancer risk association by accounting for 12 more years of follow-up and assessed whether the association varied by diabetes duration, body mass index, or waist-to-hip ratio (WHR).

Methods

Proportional hazards regression was used to estimate the hazard ratio (HR) of bladder cancer (n = 277) in relation to diabetes (before enrollment and during follow-up) and diabetes duration using a time-dependent approach.

Results

In a multivariate time-dependent analysis, the HR for bladder cancer was 1.69 (95 % CI 1.40–2.41) in relation to diabetes among 37,327 postmenopausal women initially free of cancer. There was an interaction between diabetes and WHR (p = 0.01). Bladder cancer HR in diabetic women with WHR > 0.9 was 2.5 times higher than expected. There was no dose–response relation of bladder cancer risk with diabetes duration. Compared to no diabetes, HRs were 1.77, 2.03, and 1.55 for diabetes durations of ≤5, 6–10, and >10 years, respectively.

Conclusions

We confirmed a positive association between diabetes and bladder cancer risk among white postmenopausal women. We also observed a synergistic interaction between diabetes and high WHR in bladder cancer development that might be explained by increased insulin resistance and inflammation related to abdominal obesity.
Literatur
1.
Zurück zum Zitat American Cancer Society (2012) Cancer facts & figures 2012. American Cancer Society, Atlanta American Cancer Society (2012) Cancer facts & figures 2012. American Cancer Society, Atlanta
2.
Zurück zum Zitat World Cancer Research Fund/American Institute for Cancer Research (2007) Food, nutrition, physical activity and the prevention of cancer: a global perspective. AICR, Washington DC World Cancer Research Fund/American Institute for Cancer Research (2007) Food, nutrition, physical activity and the prevention of cancer: a global perspective. AICR, Washington DC
3.
Zurück zum Zitat Freedman N, Silverman D, Hollenbeck A, Schatzkin A, Abnet C (2011) Association between smoking and risk of bladder cancer among men and women. JAMA (Chicago, IL) 306:737–745 Freedman N, Silverman D, Hollenbeck A, Schatzkin A, Abnet C (2011) Association between smoking and risk of bladder cancer among men and women. JAMA (Chicago, IL) 306:737–745
4.
Zurück zum Zitat Silverman DT, Devesa SS, Moore LE, Rothman N (2006) Bladder cancer. In: Schottenfeld D, Fraumeni JFJ (eds) Cancer epidemiology and prevention. Oxford University Press, New York, pp 1101–1128CrossRef Silverman DT, Devesa SS, Moore LE, Rothman N (2006) Bladder cancer. In: Schottenfeld D, Fraumeni JFJ (eds) Cancer epidemiology and prevention. Oxford University Press, New York, pp 1101–1128CrossRef
5.
Zurück zum Zitat Larsson S, Orsini N, Brismar K, Wolk A (2006) Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 49:2819–2823PubMedCrossRef Larsson S, Orsini N, Brismar K, Wolk A (2006) Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 49:2819–2823PubMedCrossRef
6.
Zurück zum Zitat Tripathi A, Folsom A, Anderson K (2002) Risk factors for urinary bladder carcinoma in postmenopausal women. The Iowa Women’s Health Study. Cancer 95:2316–2323PubMedCrossRef Tripathi A, Folsom A, Anderson K (2002) Risk factors for urinary bladder carcinoma in postmenopausal women. The Iowa Women’s Health Study. Cancer 95:2316–2323PubMedCrossRef
7.
Zurück zum Zitat Folsom AR, Kaye SA, Sellers TA et al (1993) Body fat distribution and 5-year risk of death in older women. JAMA 269:483–487PubMedCrossRef Folsom AR, Kaye SA, Sellers TA et al (1993) Body fat distribution and 5-year risk of death in older women. JAMA 269:483–487PubMedCrossRef
8.
Zurück zum Zitat Bisgard KM, Folsom AR, Hong CP, Sellers TA (1994) Mortality and cancer rates in nonrespondents to a prospective study of older women: 5-year follow-up. Am J Epidemiol 139:990–1000PubMed Bisgard KM, Folsom AR, Hong CP, Sellers TA (1994) Mortality and cancer rates in nonrespondents to a prospective study of older women: 5-year follow-up. Am J Epidemiol 139:990–1000PubMed
9.
Zurück zum Zitat Fritz A, Percy C, Jack A (2000) International classification of disease for oncology (ICD-O), 3rd edn. WHO, Geneva Fritz A, Percy C, Jack A (2000) International classification of disease for oncology (ICD-O), 3rd edn. WHO, Geneva
10.
Zurück zum Zitat Anderson KE, Anderson E, Mink PJ et al (2001) Diabetes and endometrial cancer in the Iowa women’s health study. Cancer Epidemiol Biomarkers Prev 10:611–616PubMed Anderson KE, Anderson E, Mink PJ et al (2001) Diabetes and endometrial cancer in the Iowa women’s health study. Cancer Epidemiol Biomarkers Prev 10:611–616PubMed
11.
Zurück zum Zitat Limburg P, Anderson K, Johnson T et al (2005) Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa women’s health study. Cancer Epidemiol Biomarkers Prev 14:133–137PubMed Limburg P, Anderson K, Johnson T et al (2005) Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa women’s health study. Cancer Epidemiol Biomarkers Prev 14:133–137PubMed
12.
Zurück zum Zitat Allison PD (2010) Survival analysis using SAS: a practical guide. SAS Institute Allison PD (2010) Survival analysis using SAS: a practical guide. SAS Institute
13.
Zurück zum Zitat ACSM’S Health-Related Physical Fitness Assessment Manual (2008) 2nd edn. Lippincott Williams & Wilkins, Philadelphia, p 59 ACSM’S Health-Related Physical Fitness Assessment Manual (2008) 2nd edn. Lippincott Williams & Wilkins, Philadelphia, p 59
14.
Zurück zum Zitat Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG (2012) Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 55:1607–1618PubMedCrossRef Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG (2012) Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 55:1607–1618PubMedCrossRef
15.
Zurück zum Zitat Colmers I, Bowker S, Majumdar S, Johnson J (2012) Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. Can Assoc Med 184:E675–E683CrossRef Colmers I, Bowker S, Majumdar S, Johnson J (2012) Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. Can Assoc Med 184:E675–E683CrossRef
16.
Zurück zum Zitat Tseng C (2012) Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 35:278–280PubMedCrossRef Tseng C (2012) Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 35:278–280PubMedCrossRef
17.
Zurück zum Zitat Mamtani R, Haynes K, Bilker W et al (2012) Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst 104:1411–1421PubMedCrossRef Mamtani R, Haynes K, Bilker W et al (2012) Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst 104:1411–1421PubMedCrossRef
18.
Zurück zum Zitat Onitilo A, Engel J, Glurich I, Stankowski R, Williams G, Doi S (2012) Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer Causes Control 23:991–1008PubMedCrossRef Onitilo A, Engel J, Glurich I, Stankowski R, Williams G, Doi S (2012) Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer Causes Control 23:991–1008PubMedCrossRef
19.
Zurück zum Zitat Evans JMM (2005) Metformin and reduced risk of cancer in diabetic patients. Br Med J 330:1304–1305CrossRef Evans JMM (2005) Metformin and reduced risk of cancer in diabetic patients. Br Med J 330:1304–1305CrossRef
20.
Zurück zum Zitat Atchison E, Gridley G, Carreon JD, Leitzmann M, McGlynn K (2011) Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer 128:635–643PubMedCrossRef Atchison E, Gridley G, Carreon JD, Leitzmann M, McGlynn K (2011) Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer 128:635–643PubMedCrossRef
21.
Zurück zum Zitat Larsson S, Andersson S, Johansson J, Wolk A (2008) Diabetes mellitus, body size and bladder cancer risk in a prospective study of Swedish men. Eur J Cancer 44:2655–2660PubMedCrossRef Larsson S, Andersson S, Johansson J, Wolk A (2008) Diabetes mellitus, body size and bladder cancer risk in a prospective study of Swedish men. Eur J Cancer 44:2655–2660PubMedCrossRef
22.
Zurück zum Zitat Noto H, Osame K, Sasazuki T, Noda M (2010) Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complicat 24:345–353PubMedCrossRef Noto H, Osame K, Sasazuki T, Noda M (2010) Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complicat 24:345–353PubMedCrossRef
23.
Zurück zum Zitat Newton C, Gapstur S, Campbell P, Jacobs E (2012) Type 2 diabetes mellitus, insulin use, and risk of bladder cancer in a large cohort study. Int J Cancer. doi:10.1002/ijc.27878 Newton C, Gapstur S, Campbell P, Jacobs E (2012) Type 2 diabetes mellitus, insulin use, and risk of bladder cancer in a large cohort study. Int J Cancer. doi:10.​1002/​ijc.​27878
24.
Zurück zum Zitat MacKenzie T, Zens M, Ferrara A, Schned A, Karagas M (2011) Diabetes and risk of bladder cancer: evidence from a case–control study in New England. Cancer 117:1552–1556PubMedCrossRef MacKenzie T, Zens M, Ferrara A, Schned A, Karagas M (2011) Diabetes and risk of bladder cancer: evidence from a case–control study in New England. Cancer 117:1552–1556PubMedCrossRef
25.
Zurück zum Zitat Tseng CH (2011) Diabetes and risk of bladder cancer: a study using the national health insurance database in Taiwan. Diabetologia 54:2009–2015PubMedCrossRef Tseng CH (2011) Diabetes and risk of bladder cancer: a study using the national health insurance database in Taiwan. Diabetologia 54:2009–2015PubMedCrossRef
26.
Zurück zum Zitat Woolcott C, Maskarinec G, Haiman C, Henderson B, Kolonel L (2011) Diabetes and urothelial cancer risk: the multiethnic cohort study. Cancer Epidemiol 35:551–554PubMedCrossRef Woolcott C, Maskarinec G, Haiman C, Henderson B, Kolonel L (2011) Diabetes and urothelial cancer risk: the multiethnic cohort study. Cancer Epidemiol 35:551–554PubMedCrossRef
27.
Zurück zum Zitat Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R (2009) Diabetes and cancer. Endocr Relat Cancer 16:1103–1123PubMedCrossRef Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R (2009) Diabetes and cancer. Endocr Relat Cancer 16:1103–1123PubMedCrossRef
28.
Zurück zum Zitat Giovannucci E, Harlan DM, Archer MC et al (2010) Diabetes and cancer: a consensus report. CA Cancer J Clin 60:207–221PubMedCrossRef Giovannucci E, Harlan DM, Archer MC et al (2010) Diabetes and cancer: a consensus report. CA Cancer J Clin 60:207–221PubMedCrossRef
29.
Zurück zum Zitat Dunn SE, Kari FW, French J et al (1997) Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 57:4667–4672PubMed Dunn SE, Kari FW, French J et al (1997) Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 57:4667–4672PubMed
30.
Zurück zum Zitat Zhao H, Grossman HB, Spitz M, Lerner S, Zhang K, Wu X (2003) Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. J Urol 169:714–717PubMedCrossRef Zhao H, Grossman HB, Spitz M, Lerner S, Zhang K, Wu X (2003) Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. J Urol 169:714–717PubMedCrossRef
31.
Zurück zum Zitat Jiang X, Castelao JE, Groshen S et al (2009) Urinary tract infections and reduced risk of bladder cancer in Los Angeles. Br J Cancer 100:834–839PubMedCrossRef Jiang X, Castelao JE, Groshen S et al (2009) Urinary tract infections and reduced risk of bladder cancer in Los Angeles. Br J Cancer 100:834–839PubMedCrossRef
32.
Zurück zum Zitat Sinha MK, Ohannesian JP, Heiman ML et al (1996) Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. J Clin Invest 97:1344–1347PubMedCrossRef Sinha MK, Ohannesian JP, Heiman ML et al (1996) Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. J Clin Invest 97:1344–1347PubMedCrossRef
33.
Zurück zum Zitat Saxena M, Agrawal C, Gautam S, Bid H, Banerjee M (2009) Overt diabetic complications in obese Type 2 diabetes mellitus patients from North India. Arch Appl Sci Res 1:57–66 Saxena M, Agrawal C, Gautam S, Bid H, Banerjee M (2009) Overt diabetic complications in obese Type 2 diabetes mellitus patients from North India. Arch Appl Sci Res 1:57–66
34.
Zurück zum Zitat Simpson C, Boyd C, Carlson M, Griswold M, Guralnik J, Fried L (2004) Agreement between self-report of disease diagnoses and medical record validation in disabled older women: factors that modify agreement. J Am Geriatr Soc 52:123–127PubMedCrossRef Simpson C, Boyd C, Carlson M, Griswold M, Guralnik J, Fried L (2004) Agreement between self-report of disease diagnoses and medical record validation in disabled older women: factors that modify agreement. J Am Geriatr Soc 52:123–127PubMedCrossRef
35.
Zurück zum Zitat Kaye SA, Folsom AR, Sprafka JM, Prineas RJ, Wallace RB (1991) Increased incidence of diabetes mellitus in relation to abdominal adiposity in older women. J Clin Epidemiol 44:329–334PubMedCrossRef Kaye SA, Folsom AR, Sprafka JM, Prineas RJ, Wallace RB (1991) Increased incidence of diabetes mellitus in relation to abdominal adiposity in older women. J Clin Epidemiol 44:329–334PubMedCrossRef
Metadaten
Titel
Diabetes and risk of bladder cancer among postmenopausal women in the Iowa women’s health study
verfasst von
Anna E. Prizment
Kristin E. Anderson
Jian-Min Yuan
Aaron R. Folsom
Publikationsdatum
01.03.2013
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 3/2013
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-012-0143-3

Weitere Artikel der Ausgabe 3/2013

Cancer Causes & Control 3/2013 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.